Partnership Opportunities

Many biotechnology and pharma companies are driving discoveries into novel and improved therapeutics in an attempt to reduce patient burden for those suffering with retinal vascular diseases. To support the prevention of blindness for potentially tens of millions of people, the Retinal Vascular Disease Drug Development Summit is uniting 80+ VPs and Directors in preclinical, translational and clinical development from biotech, and Heads of and Managers of Ophthalmology, retinal disease, ocular research from pharma pioneering developments in retinal vascular disease drug development.

This is your opportunity to showcase your scientific expertise and thought leadership to the retinal vascular community and bookmark yourself as the go-to provider of preclinical models, clinical trial services and medical devices.

Experts Need Your Help With:

  • Improving pre-clinical models to better represent how therapeutics work in the human eye
  • Reducing patient burden with the use of technologies to deliver therapeutics to the retina

And more!  

Why Partner?

favicon bullet

Showcase your expertise to industry leaders on how you can support and streamline their drug development efforts

favicon bullet

An opportunity for lead generation and to build new relationships with senior level decision makers from leading pharma and biotech companies

favicon bullet

Drive your brand exposure and set yourself apart from your competitors

Who Will You Meet?

types of companies

Past Partners:



iCare is a trusted partner in ophthalmic diagnostics, Boffering physicians fast, easy-to-use, and reliable tools for diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). Our product assortment includes automated TrueColor imaging devices, perimeters and handheld rebound tonometers. We believe that ophthalmic care should be accessible, effortless, and reliable, and we aim to establish the next level of eye care.



Experimentica is a global contract research organization developing and offering novel preclinical ocular models and services to sponsors from Pharma, Biotech, and Academia. We offer an industry-leading portfolio of in vivo, in vitro, and ex vivo PoC models in rodents and larger animals, as well as custom models, PK/PD, and Toxicity ocular studies.

Our laboratory sites are located in Finland, Lithuania, and the United States. This enables our team of interdisciplinary scientists to understand and support local and international companies fully.


Iveric bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retina diseases including earlier stages of age-related macular degeneration.



GORE is a material science company focused on discovery, product innovation and it unique culture.   With specialty in advanced fluoropolymers, it is best known for GORE-TEXÒ textiles and sutures, medical implantable devices and biopharma products.  GORE has developed advanced drug delivery & packaging offerings such as a silicone-free plunger to enable bare glass syringes for silicone-free ophthalmic/retinal injections.    

Trial Runners LOGO

Trial Runners

Since 2006, Trial Runners has provided a full scope of services to the clinical research industry; organizations—biotechs, pharmaceutical companies of all sizes, and others—have worked with us on several clinical trials. Within ophthalmology, we have garnered experience spanning across both the front and back of the eye, all while consistently meeting Sponsor needs and sculpting a workplace that continuously meets our experts’ needs and desires. In total, we’ve managed 80+ trials of all phases across 19 countries that have included more than 10,000 patients.

Trial Runners has also been involved with several gene therapy clinical trials. While gene therapy itself is still a relatively new and developing treatment option, we’re proud to be involved with this branch of therapeutics that involves various treatments and outcomes that are promising in nature. We’re both eager and excited to be on the cutting-edge of new advancements, and we’re equally as honored to play our part in shaping these clinical trials.

Diagnosys LLC LOGO


Diagnosys offers a full suite of clinical electrophysiology and psychophysical tests that comprehensively and objectively test the function of the retina.  

Building upon our years of experience working with clinical trials, we have expanded our services to support all phases of clinical trials including setup, training, and quality interpretation of test data. 

Occutrack Medical Solutions Pte Ltd logo


Occutrack is developing a patented home-based telemonitoring system to track AMD so that both early onset of AMD and disease progression may be effectively monitored to prevent further deterioration of central vision loss.

Occutrack’s machine-vision technology applies gaze-tracking oculometrics that senses the saccadic movement of the human eye in response to generated stimuli on a monitor screen.

Consistent monitoring and timely treatment of an individual suffering from AMD can stop and prevent further deterioration of central vision loss, thus improving the quality of life.


Ellie Bilko
Partnerships Manager